ISAL 2019 | Christoph Röllig on AML research in Dresden, Germany

Christoph Röllig

Christoph Röllig, MD, MSc, discusses the ongoing research into acute myeloid leukemia (AML) at his insitute, Dresden University of Technology, Dresden, Germany. He highlights the coordination of clinical trials, treatment sites and registries. Dr Röllig also discusses the DaunoDouble trial (NCT02140242), with further results expected to be presented at ASH 2019. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video